- Home
- WD vs CLDX Comparison
WD vs CLDX Comparison
Compare WD & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WD | CLDX |
|---|---|---|
| Founded | 1937 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2010 | 1995 |
Fundamental Metrics
Financial Performance| Metric | WD | CLDX |
|---|---|---|
| Price | $55.22 | $33.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $76.00 | $46.60 |
| AVG Volume (30 Days) | 191.0K | ★ 671.7K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $1,234,306,000.00 | $12,743,000.00 |
| Revenue This Year | $20.60 | $111.39 |
| Revenue Next Year | $7.79 | $235.85 |
| P/E Ratio | $118.91 | ★ N/A |
| Revenue Growth | 8.99 | ★ 87.78 |
| 52 Week Low | $42.12 | $18.56 |
| 52 Week High | $90.00 | $35.83 |
Technical Indicators
Market Signals| Indicator | WD | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 72.44 | 54.30 |
| Support Level | $42.34 | $28.30 |
| Resistance Level | $66.25 | $35.18 |
| Average True Range (ATR) | 1.84 | 1.38 |
| MACD | 0.52 | -0.13 |
| Stochastic Oscillator | 81.69 | 55.59 |
Price Performance
Historical ComparisonAbout WD Walker & Dunlop Inc
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.